BCM
GBT

Bayesian Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bayesian Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,600
Closed -$610K – 1192
2022
Q1 		$610K Buy
+17,600
New +$526K 0.09% 329

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bayesian Capital Management's GBT Position: Q2 2022 in Review

Bayesian Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 17,600 shares — an estimated $610K sold.

Bayesian Capital Management first reported a position in GBT in Q1 2022 and held it in 1 quarter. The position peaked at $610K in Q1 2022. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Bayesian Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 17,600 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $610K.
  • Bayesian Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Global Blood Therapeutics, Inc. position peaked at $610K in Q1 2022.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.